Trevo NXT™
ProVue Retriever
Take thrombectomy to the next level
Trevo NXT™
ProVue Retriever
Feel the difference with smooth retrieval
The combination approach of stent retrievers with aspiration has become one of the most preferred approaches for thrombectomy. That's why we're introducing the Trevo NXT ProVue Retriever as part of a solution optimized for this technique. We've kept the same highly effective Trevo Retriever stent design while introducing a TriGlide Delivery Wire, for smoother and easier delivery and retraction into the aspiration catheter.
The responsive TriGlide Delivery Wire makes using the Trevo NXT ProVue Retriever feel easy, so you can work with speed to get to and remove the clot.
65% less retraction force
into an intermediate catheter due to the TriGlide Delivery Wire.
With the Trevo NXT ProVue Retriever, you can deliver the full range of Trevo NXT ProVue Retriever sizes through the Trevo Trak 21 Microcatheter without compromising on the stent design you trust.
Trevo retrievers are designed to maximize clot integration and provide meaningful procedure guidance with full-length radiopacity.
Timeline
7,000+ patients have been studied across RCT's, registries, and observational studies.*
MR CLEAN:
Multicenter, randomized clinical trial comparing MT in addition to guideline approved medical management with medical management alone. Showed 32.6% of MT treated patients had functional independence at 90 days vs. 19.1% in the control group (primary endpoint).5
DAWN Trial:
Randomized, open-label trial compared Trevo Retriever thrombectomy plus standard medical care with standard medical care alone for patients up to 24 hours from symptom onset. 49% of patients in the treatment arm were functionally independent at 90 days vs. 13% in the control group (primary endpoint).7
Trevo Retriever Registry:
Prospective, post-market, global study to evaluate reperfusion at endof procedure and functional outcomes at 90 days in patients treated with Trevo Retriever. Results from the 2008 patients show TICI 2b/3 in 92.8% of patients with functional independence at 90 days in 55.3%.8
* Studies conducted using Trevo XP which has been shown to be substantially equivalent to Trevo NXT.
StrokEnomics™
Economic impact
First-pass effect (FPE) is predictor of favorable clinical and economic outcomes.11 The TREVO registry12 has demonstrated that FPE resulted in improved clinical outcomes, which it can be translated into lower healthcare resource use. From the TREVO registry, we can estimate the following savings per procedure in the top 5 EU countries.13
| Estimated hospitalization-related cost savings | |
| France | € 190 |
| Germany | € 426 |
| Italy | € 430 |
| Spain | € 901 |
| UK | £ 612 |
A.)
Same proven stent
Large cells, tailored radial force, tubular design, for consistent integration
B.)
TriGlide Delivery Wire
Nitinol core wire with hydrophilically coated polymer jacket reduces friction
C.)
Longer 200cm nitinol delivery wire
for compatibility with tri-axial setups
Specifications
| Stent diameter | Labeled length | Stent length | Device length | Wire diameter | |
| 90412 | 3 | 32 mm | 36 mm | 200 cm | 0.015 in |
| 90413 | 4 | 28 mm | 32 mm | 200 cm | 0.019 in |
| 90414 | 4 | 41 mm | 44 mm | 200 cm | 0.019 in |
| 90415 | 6 | 37 mm | 40 mm | 200 cm | 0.019 in |
Compatibility
| Trevo NXT ProVue Retriever | Compatible microcatheter | Recommended Minimum Vessel ID (mm) |
| 3x32 | Trevo Pro 14 Microcatheter Trevo Trak 21 Microcatheter |
1.4 |
| 4x28 | Trevo Trak 21 Microcatheter | |
| 4x41 | Trevo Trak 21 Microcatheter | |
| 6x37 | Trevo Trak 21 Microcatheter | 2.5 |
Capture technique
A) AXS Universal
Aspiration System
B) AXS Infinity LS Plus
Long Sheath
C) AXS Vecta 74
Intermediate Catheter
D) Trevo NXT
ProVue Retriever
Trevo Trak 21
Microcatheter
Trap technique
A) Trevo NXT
ProVue Retriever
Trevo Trak 21
Microcatheter
B) AXS Catalyst 7
Distal Access Catheter
C) FlowGate2
Balloon Guide Catheter
D) AXS Universal
Aspiration System
Trevo/TRAP animation video
- MERCI Multi Merci listed by study enrollment dates. Smith, Wade S., et al. “Mechanical Thrombectomy for Acute Ischemic Stroke.” Stroke, vol. 39, 28 Feb. 2008, pp. 1205–1212, https://doi.org/10.1161/strokeaha.107.497115.
- MERCI Registry listed by study enrollment dates. “Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke - Full Text View.” ClinicalTrials.Gov, 24 May 2007, classic.clinicaltrials.gov/ct2/show/study/NCT00478478.
- TREVO listed by study enrollment dates. Jansen, Olav, et al. “Neurothrombectomy for the Treatment of Acute Ischemic Stroke: Results from the Trevo Study.” Cerebrovascular Diseases, vol. 36, no. 3, 12 Oct. 2013, pp. 218–225, https://doi.org/10.1159/000353990.
- TREVO 2 listed by study enrollment dates. Nogueira, Raul G, et al. “Trevo versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial.” The Lancet, vol. 380, no. 9849, 26 Aug. 2012, pp. 1231–1240, https://doi.org/10.1016/s0140-6736(12)61299-9.
- MR CLEAN listed by study enrollment dates. Berkhemer, Olvert A., et al. “A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke.” New England Journal of Medicine, vol. 372, 1 Jan. 2015, pp. 11–20, https://doi.org/10.1056/nejmoa1411587.
- TRACK Registry listed by study enrollment dates. Zaidat, Osama O, et al. “Trevo Stent-Retriever Mechanical Thrombectomy for Acute Ischemic Stroke Secondary to Large Vessel Occlusion Registry.” Journal of NeuroInterventional Surgery, vol. 10, no. 6, 29 Sept. 2017, pp. 516–524, https://doi.org/10.1136/neurintsurg-2017-013328.
- DAWN Trial listed by study enrollment dates. Nogueira, Raul G., Ashutosh P. Jadhav, et al. “Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.” New England Journal of Medicine, vol. 378, 4 Jan. 2018, pp. 11–21, https://doi.org/10.1056/nejmoa1706442.
- Trevo Registry aka Trevo 2000 Registry listed by study enrollment dates. Binning, Mandy J., et al. “Trevo 2000: Results of a Large real‐World Registry for Stent Retriever for Acute Ischemic Stroke.” Journal of the American Heart Association, vol. 7, no. 24, 18 Dec. 2018, https://doi.org/10.1161/jaha.118.010867.
- ASSIST Registry listed by completion date, defined here as date that final data were received by Stryker. Data on file.
- Information about Trevo China, Trevo Japan, and ongoing investigator initiated studies on file at Stryker.
- Zaidat et al 2020, Health economic impact of first-pass success among patients with acute ischemic stroke treated with mechanical thrombectomy: a United States and European perspective. J NeuroIntervent Surg 2020;0:1–7. doi:10.1136/neurintsurg-2020-016930
- Jadhav et al. 2021. First pass effect in patients with large vessel occlusion strokes undergoing neurothrombectomy: insights from the Trevo Retriever Registry. J NeuroIntervent Surg 2021;0:1–5. doi:10.1136/neurintsurg-2020-016952
- Cost savings estimates based on FPE vs. Non-FPE from TREVO registry. The per-day hospitalization-related cost rates published in Supplemental Table 1 of Zaidat et al (2020) reported as 2020 currencies. Hospitalization-related cost savings do not account for procedural/device-related costs. UK cost savings estimate is based on ICU LOS per-day cost rate only, while cost savings estimates for France, Germany, Italy, and Spain reflect blended rates across ICU and standard beds.
This content is intended solely for the use of healthcare professionals.
A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
AP003649 V 3.0